Non-formulary **alirocumab (PRALUENT)** will be covered on the prescription drug benefit when the following criteria are met:

**Clinical ASCVD** (examples include: heart attack or stroke)
- Prescribed by a cardiologist or an endocrinologist
- Age 40 years or older
- Receiving cholesterol lowering medications for at least 3 months including ezetimibe AND *statin therapy
- Statin adherence rate of greater than or equal to 85% that is verified from PST or pharmacy dispensing history
- Inadequate LDL reduction based on the statin intensity
- LDL greater than or equal to 70 mg/dL on statin therapy
- Trial and failure with evolocumab (Repatha)

**New members stable on alirocumab for at least 4 weeks or longer:**
- Receiving ezetimibe 10 mg/day unless patient suffered from recurrent ASCVD events
- LDL decreased by ≥ 50% on alirocumab compared to pre-alirocumab levels
- Trial and failure with evolocumab (Repatha)

**Heterozygous Familial Hypercholesterolemia**
- Prescribed by a cardiologist or an endocrinologist
- Age 18 years or older
- Not receiving LDL apheresis
- Receiving cholesterol lowering medications for at least 3 months including ezetimibe AND *statin therapy
- Statin adherence rate of greater than or equal to 85% that is verified from PST or pharmacy dispensing history
- LDL greater than or equal to 190 mg/dL within the last 3 months on statin and ezetimibe
- Trial and failure with evolocumab (Repatha)

**New members stable on alirocumab for at least 4 weeks or longer:**
- In addition to above criteria: LDL decreased by ≥ 50% on alirocumab compared to pre-alirocumab levels
- Trial and failure with evolocumab (Repatha)

ASCVD=atherosclerotic cardiovascular disease; LDL=low-density lipoproteins; PST=patient support tool

*Statin Therapy:
- Maximum dose of high intensity statin
- Maximally tolerated dose equivalent to atorvastatin 20 mg/day with documentation of trials and intolerance of both atorvastatin and rosuvastatin
- Drug interaction precluding the use of atorvastatin 80 mg/day AND rosuvastatin 40 mg/day and the dose is at minimum equivalent to atorvastatin 20 mg/day